Testing Risk, Managing Harm: Ethical Challenges of Population Genomic Screening for BRCA Mutations in Ashkenazi Jewish Women

What if a simple genetic test could warn someone about a life-threatening risk of cancer before any symptoms appear? As population genomic screening becomes more common, especially among higher-risk groups like Ashkenazi Jewish women, medicine faces a difficult ethical dilemma regarding how far public health systems should go in identifying genetic risk. While these screenings have the potential to save lives through early detection and prevention, they also raise concerns about privacy, stigma, and informed consent. This paper examines the ethical justification of BRCA population genomic screening.

Table of Contents

• Introduction

• Background

  1. BRCA Gene

  2. Population Genomic Screening

  3. Genetic Counseling

  4. Sponsorship and Governance

  5. Economic Implications

• Screening Applications

  1. BRCA Mutation Case Study

  2. Sickle Cell Disease Case Study

  3. Case Study Comparisons and Summary

• Challenges

  1. Psychological Challenges

  2. Challenges of Privacy

  3. Societal Challenges

• Ethical Analysis

  1. Deontology

  2. Consequentalism

• Conclusion

Featured Image: http://rawpixel.com

Introduction

Credit: Wellbeing of Women

Imagine a woman participating in a community-based genetic screening program gains access to testing that she might not otherwise have pursued and learns that she carries the BRCA gene mutation, despite having no prior family history of breast or ovarian cancer. What began as a routine public health encounter quickly becomes a life-altering moment, forcing her to face complex medical decisions about increased surveillance, preventive surgeries, and reproductive planning. At the same time, her result introduces uncertainty and potential strain within her family, as relatives must grapple with their own possible risks and the weight of newly uncovered genetic information.

This paper acknowledges the broader expansion of genetic testing in modern medicine and its growing role in public health decision-making. Genetic testing has evolved significantly and continues to change. The Human Genome Project was a 13-year international science project spanning 1990-2003 that successfully mapped and sequenced the entire human genome blueprint. As a result, scientists identified roughly 20,000-25,000 human genes and mapped their locations. This project provided the foundation for modern medicine, allowing researchers  to understand genetic diseases, develop new treatments, and improve diagnostics (“The Human Genome Project”). In relation to population genomic screening, this movement has enabled a shift from reactive medicine to predictive, population-level screening. Now, researchers are able to identify gene variants that increase the risk of disease.

Inherited mutations in the BRCA1 and BRCA2 genes dramatically increase the risk of breast and ovarian cancer, with those affected having a 45%-85% chance of developing breast cancer and a 10%-46% chance of ovarian cancer (“Inherited Cancer Risk: BRCA Mutation”). Generally, it has been thought that only those with a family history of the disease or mutation would be recommended to undergo genetic screening, however, recent studies have shown otherwise. The Breast Care Center at the University of California at San Francisco has recently completed a large national trial that led to a prominent finding—30% of women who tested positive for genetic mutations cited no family history of breast cancer (Wen). With these factors considered, there has been an increased interest in population genomic screening for the BRCA mutation.

This project will explore whether population genomic screening for BRCA mutations is ethically justified for Ashkenazi Jewish women, analyzing the tension between public health benefits, individual autonomy, and communal concerns. To contextualize these concerns, I will draw parallels to earlier population genomic screening programs, such as sickle cell anemia testing among African and African American communities. Using this case as an example, I will illustrate how well-intentioned public health initiatives can produce unintended ethical harms. 

Population genomic screening for a specific ethnic group is distinctive from other public health initiatives because it risks reinforcing biological definitions of identity. With this in mind, ethical complexities are introduced in relation to stigma and past discrimination. Evaluating the ethical implications, I will employ frameworks such as deontology, consequentialism, and the principles of bioethics, including autonomy, justice, beneficence, and nonmaleficence. With this analysis, I will ultimately answer my central ethical question: Under what conditions might population genomic screening for Ashkenazi Jewish women be ethically justified to both patients and public health systems, and how do factors like funding source, access, and healthcare context shape these ethical considerations?

Background

Credit: uranj.com

BRCA Gene:

The name of the BRCA gene, referring to the two genes BRCA 1 and BRCA 2, is derived from the words breast cancer (BReAst CAncer). When these genes function as designed, they repair DNA and prevent cancerous changes in cells. However, if a mutation occurs and damages either of these genes, a patient’s risk for cancer increases. For women, there is a significant increase in the risk for breast or ovarian cancer as well as an increased risk for pancreatic cancer in men. These gene mutations can be inherited by an individual’s biological children in some cases (“Inherited Cancer Risk: BRCA Mutation”).

Population Genomic Screening:

When considering the background of population genomic screening it is important to make distinctions between other common forms of genetic testing that are already in place within clinical practices. Universal screening, for example, applies the same genetic tests to all individuals within a defined clinical context (such as newborns or all pregnant women), whereas population genomic screening targets specific subgroups defined by ancestry, ethnicity, geographic origin, age, or known risk factors. In contrast, individual clinical testing is ordered based on a patient’s symptoms or family history (Cline and Holdren). Population genomic screening is a public health approach that tests the DNA of a wide group of people, based on age, region, or community. This is done regardless of a patient's symptoms or family history and is used to identify genetic risks for diseases that can be treated or prevented more effectively when detected early. This can be accomplished within community-based screening programs through clinics, religious institutions, or outreach initiatives (“Population Genomic Screening”). While these programs are beneficial for preventive care, they raise ethical considerations regarding privacy, informed consent, and cultural or religious obligations. These particular considerations include, but are not limited to, concerns in relation to unauthorized data sharing due to large groups of personal information, or the obligation one has in sharing genetic information to their potential spouse. Specifically, many from the Orthodox Jewish Community consult with Rabbis in order to determine when screening is permissible.

This paper focuses on voluntary participation in population genomic screening, meaning it is assumed that those who engage in testing are doing so by exercising their own autonomy. These population genomic screening programs are driven by public health objectives, such as early detection and disease prevention. With early detection of the BRCA mutation from screening, individuals are enabled to pursue increased surveillance and preventive medical interventions. 

Genetic Counseling:

The process of genetic screening is not just limited to a test, as there are also specific processes in which testing results and information is communicated. This is known as genetic counseling. This form of counseling is first introduced prior to screening, to understand the testing process and interpret results. If there is a family history of a certain genetic mutation, the genetic counselor will map out the patient’s family tree, including the age at which family members were diagnosed and whether they are still living, to visualize how one’s history may affect their children. Furthermore, the counselor will discuss current legislation in place that protects genetic information. If the patient decides to undergo testing, the counselor provides assistance in understanding DNA testing options as well as scheduling appointments. After testing and receiving the results, a patient has a follow up meeting with the counselor to interpret one’s risk for developing a certain condition. Additionally, they will also discuss future health plans, which may include further testing or potential treatment options (“Genetic Counseling”). In modern-day genetics, this process has become much more common and deemed as a necessity. However, past implementations of screening have failed to incorporate this practice, one of which I will discuss in an upcoming section.

Sponsorship and Governance:

There are many forms of sponsorship for population genomic screening as part of disease prevention efforts, such as the government and public health agencies. Additionally, healthcare systems may also sponsor screening initiatives in partnership with insurers. These organizations view genetic testing as a tool to improve population health outcomes and to reduce long-term healthcare costs associated with advanced disease treatment.

Furthermore, academic medical centers and research institutions frequently lead population genomic screening programs to advance scientific knowledge, develop new prevention strategies, and study genetic patterns within specific populations. In order to increase awareness and access within specific cultural or ethnic communities, nonprofit and community-based organizations often sponsor or facilitate screening programs (Khoury and Dotson). One of the largest community-based population health programs in the world is Renown’s Healthy Nevada Project. This nonprofit organization offers screening for three clinically actionable genetic mutations, including the BRCA 1 & 2 gene mutations. Included in the study is free genetic counseling with a licensed genetic counselor in order to interpret results after completing a test (“Genetic Testing FAQ”).

Economic Implications:

When determining the best treatment for patient populations, healthcare professionals analyze evidence of both the health benefits and economic costs. To do so, the U.S. health system utilizes what is known as cost-effective analysis. The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research organization that evaluates the clinical effectiveness and value of medical tests, treatments, and prescription drugs.

Within this process is the Quality-Adjusted Life Year (QALY) that is used to determine how medical treatments improve or lengthen lives. If evidence proves either to be positive, then those benefits are summed up together to determine how many additional QALYs the treatment ensures as well as developing a comparative analysis to other treatments for the same patient population. In addition to QALYs, ICER also includes a calculation of the Equal Value of Life Years (evLY). This examination is a way of measuring the benefit of a treatment where every extra year of life is counted the same, no matter the person’s health or quality of life. For example, if genetic testing shows that a woman has a BRCA mutation, she may choose preventive treatments that lower her risk of cancer and help her live longer. If those treatments add one extra year to her life, evLY would count that year the same as an extra year gained by someone without a genetic risk, because every additional year of life is valued equally (“Cost-Effectiveness, the QALY, and the evLY”).

To summarize, the BRCA gene mutation disrupts the typical functionality of the gene and inhibits its ability to prevent the creation of cancerous cells. Population genomic screening is a form of widespread genetic testing that looks to genetically test specific populations based on a specific shared commonality, such as age or ethnicity, in order to identify genetic risks of disease. This form of testing is based on voluntary participation and these screening programs emphasize the importance of preventive medical care for actionable diseases. In order to understand the process of testing and interpret results, patients undergo genetic counseling. These screening programs may receive sponsorships through many different forms of funding, such as government, public health agencies, grants, academic medical centers, nonprofit organizations, etc. Often, the economic and social benefits of a public health initiative can be measured by applying the methodology of cost-effective analysis alongside the Quality-Adjusted Life Year (QALY) and Equal Value of Life Years calculations (evLY).

Screening Applications

Credit: Wikimedia Commons

BRCA Gene Mutation Case Study:

As a result of the founder effect, Ashkenazi Jewish women have a much higher susceptibility for having these mutations than the general population. The founder effect occurs when a small population of individuals experience historical isolation, leading to a lack of genetic variation (“Updates in BRCA testing for People of Ashkenazi Jewish Ancestry”). Ashkenazi Jews are individuals of Eastern and Central European Jewish ancestry. This specific population of 10 million individuals make up an estimated 75%-80% of the world’s total Jewish population (“Ashkenazi Jewish Heritage and BRCA mutations”). Due to such an increased occurrence of this specific genetic mutation within this group, community-based screening initiatives have been developed through partnerships with synagogues, cultural organizations, and local clinics to provide accessible testing and education programs.

Within Judaism, Pikuach Nefesh is a principle that prioritizes the preservation of life above most religious laws, shaping community attitudes towards genetic testing and generally reinforcing the acceptance of BRCA screening as a form of preventive care (Lopatin).

Specifically, Sharsheret is a nonprofit organization that aims to support Jewish women and families facing breast and ovarian cancer. The organization provides many different forms of programming, including genetic counseling services for those undergoing testing (“BRCA/Genetics”). Counseling services are essential in this context, as BRCA screening carries gendered implications for women, who bear the primary physical, emotional, and social burden of testing decisions related to cancer risk, reproduction, and preventive surgery. Furthermore, knowledge of BRCA mutation status can significantly shape family and reproductive decisions, including choices about marriage, childbearing, and preventive medical interventions, while raising ethical questions about the responsibility to inform family members of shared genetic risk. The impact of BRCA mutation screening varies across levels of religious observance, with more Orthodox Jewish communities often emphasizing communal responsibility and disclosure, while less observant or secular Jewish populations frame testing primarily as an individual medical decision. In certain Orthodox communities, genetic testing is incorporated in premarital screening programs. The increase in screening, through population genomic screening, may lead to the disclosure of a BRCA mutation becoming a factor in marriage arrangements (Yi et al.).

While population genomic screening for the BRCA mutation has not been fully implemented within the United States, several international pilot programs demonstrate how such a model could function in practice. For example, the UK’s National Health Service (NHS) East London Genes & Health study has explored large-scale community-based genetic screening within diverse populations to identify actionable variants and connect participants with clinical follow-up care. Specifically for the BRCA gene mutation, they provided genetic testing for individuals with at least one reported Ashkenazi Jewish grandparent. Out of 5,389 people who referred themselves, 4,339 (about 80.5%) agreed to take the genetic test. Among those who received their results, 2.3% (98 out of 4,274 people) were found to carry a pathogenic genetic variant linked to increased disease risk. Most of these variants (about 89.8%) were common “founder” mutations associated with Ashkenazi Jewish populations, while the remaining 10.2% were other non-founder variants (Torr, Bethany et al).

Sickle Cell Disease Case Study: 

An example of a past implementation of population genomic screening is sickle cell disease (SCD). SCD is a disease that affects about 100,000 people in the United States and more than 90% are non-Hispanic Black or African American (“Data and Statistics on Sickle Cell Disease”). In the time between 1970 and 1972, mandatory sickle cell screening laws for African-American citizens were enacted in 12 states and the District of Columbia, along with increased federal support and treatment regarding sickle cell anemia during 1971. However, these laws failed to address the risks associated with the stigmatization of African-Americans who not only carried the disease, but also possessed the genetic mutation in the HBB gene on chromosome 11. The greatest effects of this implementation were in regards to racial issues. Specifically, the language used by a New York State law stated that all people, “not of the Caucasian, Indian, or Oriental races” be screened for the sickle cell trait before receiving a marriage license, illustrating the belittling tone used at the time. This is further emphasized by using improper scientific language, labeling the blood dyscrasia as a “communicable disease”, a term generally used for infectious diseases instead of those which are inherited, which conveyed inaccurate information that patients needed to be isolated. Furthermore, the lack of informed consent and genetic counseling led to a gray area surrounding those with carrier status of the mutation and those who had disease status.

Screening programs historically focused on identifying carriers of the sickle cell trait as well as individuals with the disease, but this distinction was not always clearly communicated, leading to confusion about personal and familial risk. These failures contributed to significant stigma, including discrimination in employment, insurance, and social standing, as individuals were labeled based on carrier status rather than actual disease. The combination of inadequate counseling, coercion, and societal bias constitutes a notable ethical failure and demonstrates how well-intended public health efforts can harm vulnerable populations. Despite these failures, the implementation of past screening programs for sickle cell anemia has led to a significant reduction in infant mortality, and has now become a universal newborn screening (NBS) within the United States (Markel). This mandatory testing is administered within 24-48 hours of birth, usually involving a heel-prick blood test (“Sickle cell anemia”).

Case Study Comparisons and Summary:

When comparing these distinct eras of population genomic screening, it is important to highlight the many differences between them. Most notably, the advocated population genomic screening efforts for the BRCA gene mutation are voluntary and community driven, emphasizing freedom of choice. Conversely, the past sickle cell anemia testing was mandatory within certain states, targeting African American citizens. Additionally, the vital role of genetic counseling is further emphasized through the experiences of sickle cell patients during the 1970s, who lacked the knowledge of important information regarding their testing results. Now, there is a much stronger emphasis on counseling in the world of genetic testing, such as through the previously mentioned organization Sharsheret, as it allows patients to preserve their autonomy through an informed decision-making process. 

Furthermore, there is a significant difference in the alignment of cultural values between both respective screenings. Within Jewish culture, there is the previously mentioned principle of Pikuach Nefesh, which shapes the community’s positive outlook on screening as a potential life-saving action. However, there is no comparable cultural framework to support SCD screening as it was instead shaped by racial bias and discrimination. It is also important to compare the historical time period in which each screening occurred. BRCA mutation testing is applicable to more modern medicine where there is a generally greater understanding of healthcare and the healthcare system. However, the time of SCD testing was the post civil rights era where there was deep mistrust in medicine due to systemic racism. Taken together, these differences demonstrate that the success of population genomic screening is not solely determined by scientific advancement, but rather highlight the importance of informed consent, cultural sensitivity, and equitable practices in shaping the future of genomic medicine.

Credit: Wikimedia Commons

Challenges

Although BRCA genetic testing provides individuals with valuable information regarding their health risks and opportunities for early intervention, it also introduces a range of complex challenges that extend beyond the clinical setting. These challenges are multifaceted, encompassing psychological, personal, social, and ethical dimensions that can significantly shape an individual’s experience with testing. The process of deciding whether to undergo testing, interpreting results, and determining appropriate next steps can create uncertainty and difficult decision-making for patients and their families. Additionally, the implications of genetic information often extend beyond the individual, raising concerns about familial responsibility, privacy, and potential discrimination. Together, these factors highlight the broad and interconnected nature of the challenges associated with BRCA testing.

Psychological Challenges:

Psychological challenges commonly affect both patients considering testing and patients who have tested positive for the BRCA mutation. Those contemplating testing may have fear regarding the possibility of their test results being positive and what future health decisions may await. Similarly, patients who have the genetic mutation may be unsure of what care to proceed with, such as increased preventive screenings, explore the use of chemopreventive drugs, or more extremely, prophylactic surgery. Additionally, testing positive for the BRCA mutation can bring other stakeholders into the situation. Variations in a patient’s genetic makeup may have implications for the health of family members, potentially straining personal relationships (Hamilton et al).

Challenges of Privacy:

The challenges of privacy are evident in direct-to-consumer (DTC) services as they pose potential risks of unauthorized data sharing with third parties, potential exposure in data breaches, and use by law enforcement. Many DTC genetic tests are not regulated by the Health Insurance Portability and Accountability Act (HIPAA). HIPAA was enacted in 1996 and is a U.S. federal law designed to protect sensitive information from disclosure without consent. It mandates national standards for electronic health transactions, privacy, and security, applying to healthcare providers, plans, and clearinghouses. While this act protects data used in clinical settings, it does not apply to non-covered entities, such as most DTC testing companies or research institutions (“Summary of the HIPAA Privacy Rule”). For example, although companies such as 23andMe state that their systems are designed to align with HIPAA Security Rule standards for protecting health-related data, they are not classified as HIPAA-covered entities and therefore are not legally required to comply with HIPAA regulations. This gap became more visible following its 2025 bankruptcy, when concerns emerged about how consumer genetic data could be stored, accessed, or transferred during financial restructuring (“Trust Center”). This emphasized that protections for DTC genetic information rely largely on company policy rather than federal enforcement. 

In addition to HIPAA, there are also concerns regarding the Genetic Information Nondiscrimination Act (GINA). This is a U.S. federal law that protects against genetic discrimination in the workplace. In general, the protections of this act are limited to health insurance, meaning it does not cover life, disability, or long-term care insurance. This law also has exceptions including the exclusion of small businesses with fewer than 15 employees and those receiving insurance from the federal government or military (“Genetic Information Discrimination | U.S. Equal Employment Opportunity Commission”).

Additionally, GINA only eliminates discrimination based on genetic information regarding a patient who has not yet been diagnosed with a disease. Through screening, individuals may learn they carry a BRCA mutation long before any symptoms appear, and they may use this information to pursue preventive care such as increased surveillance or prophylactic surgery. However, if a BRCA mutation is treated as a form of disease manifestation rather than a risk indicator, then protections under GINA and HIPAA may not fully apply, creating uncertainty in how this information is regulated and protected (“Genetic Information Privacy”).

Societal Challenges:

In addition to psychological and privacy-related challenges, population genomic screening also raises significant societal concerns. As testing becomes increasingly normalized, individuals with identified at-risk ethnic or demographic groups may experience heightened social pressure to undergo screening in alignment with prevailing norms. This normalization can unintentionally contribute to stigma, as those who test positive or are deemed high-risk may be subject to disproportionate social expectations or burdens. Linking specific genetic mutations to certain populations can lead to genetic essentialism. Genetic essentialism is the cognitive bias of oversimplifying human traits, behaviors, and social categories by attributing them solely to an underlying, unalterable “essence” found in DNA (Dar-Nimrod and Heine). In other words, this occurs when people incorrectly reduce complex biology to simple group labels, which reinforce stereotypes. 

From a policy perspective, population genomic screening initiatives often reflect elements of soft-paternalism, in which behavioral nudges are employed to encourage health-promoting decisions while preserving individual autonomy (Dworkin). Given the societal interest in reducing cancer prevalence and improving population health outcomes, governments and health institutions may reasonably justify strategies such as targeted education campaigns, reminders, and opt-out screening frameworks. These approaches aim to increase participation without resorting to coercive mandates, thereby attempting to balance public health objectives with respect for individual choice. 

Additionally, past unethical medical research continues to shape public trust in healthcare systems and genetic science, influencing how communities perceive and respond to contemporary population genomic screening initiatives. This medical mistrust is deeply shaped by historical failures in abiding by ethical standards, particularly abuses committed in earlier medical research. The atrocities of Nazi human experimentation during the Holocaust heavily contributed to the establishment of modern bioethical standards, especially the importance of informed consent and lack of coercion within the medical research process. These reforms emerged from the belief that scientific authority, without proper legislation in place, can severely violate human rights and undermine the legitimacy of medical institutions. Present-day mistrust of medical and genetic institutions is deeply rooted in historical abuses of vulnerable populations. This skepticism affects how communities interpret population genomic screening initiatives, raising fears about misuse of genetic data, discrimination, and emphasizing the importance of personal control over biological information (Shuster).

Overall, population genomic screening highlights the difficult balance between scientific progress and its social and ethical implications. The outcomes of genetic screening are shaped as much by social context as by medical technology itself, particularly in terms of consent, education, and respect for individual autonomy. The modern challenges surrounding BRCA testing, related to psychological, privacy, and societal concerns, further reinforce that genetic testing is not purely clinical and has many ethical dimensions to consider.

Credit: Cutler Integrative Medicine

Ethical Analysis

To address the central ethical question of this paper—under what conditions might population genomic screening for Ashkenazi Jewish women be ethically justified to both patients and public health systems, and how do factors like funding source, access, and healthcare context shape these ethical considerations—I will employ a consequentialist analysis in collaboration with a deontological perspective. This analysis will allow me to explain what duties must be upheld before examining the potential outcomes. In addition to this overarching question, this analysis also considers several related concerns: What duties does society have to vulnerable populations? Should medical resources be prioritized for higher-risk groups? And to what extent can identity be incorporated into healthcare without reinforcing discrimination? I will evaluate the ethical justification separately from the perspective of individual patients and public health systems, as these groups may have competing interests. Based on the following analysis, I believe that population genomic screening is ethically justified for both patients and public health systems.

Deontology:

Deontology is an ethical theory that judges the morality of actions based on rules, duties, and intentions rather than consequences. From a deontological perspective, the ethical evaluation of population genomic screening of the BRCA genetic mutation depends on whether it upholds core moral duties such as the autonomy of patients, as well as the responsibility of public health systems. These forms of systems, such as governments and institutions, have a duty to protect and promote public health by preventing disease and ensuring equitable access to care. In terms of the distinction between equity and equality, equality refers to providing the same resources and opportunities to everyone, and contrastingly, equity recognizes the specific circumstances of individuals and applies that to the process of resource allocation. 

For population genomic screening of the BRCA mutation, those who have Ashkenazi Jewish ancestry are deemed to have a higher risk of having the genetic mutation in comparison to the general population, making the allocation of resources to this specific group equitable (“Updates in BRCA testing for People of Ashkenazi Jewish Ancestry”). These health-related duties must be balanced with the respect of the rights of individuals, specifically when considering participation in genomic screening programs. So, the specific screening programs must aim to reduce disease and improve health outcomes without pressuring certain communities with shared genetic ancestry into participation through coercion or mandatory policy. 

In addition, institutions sponsoring screening must clearly outline its purpose, potential benefits, and limitations so that individuals can make genuinely informed decisions. Institutions also bear the responsibility of ensuring that consent is truly informed and voluntary by providing clear, accessible explanations of genetic risks, outcomes, and data use, rather than relying on assumptions of known information or social pressure to secure participation. A central requirement, therefore, is that patients receive fully transparent and comprehensible genetic counseling so they can make informed decisions about whether to undergo testing and how to interpret results (“Genetic Counseling”). Without effective articulation of these risks, limitations, and potential consequences, BRCA population genomic screening would violate the principle of autonomy for patients, regardless of any medical benefit produced.

 From the perspective of public health systems, governments have a responsibility towards the entire population. This includes those who may not be a part of the ethnic group in question, as they still have a risk of developing the genetic mutation, regardless of the chance being statistically much smaller and occurring more arbitrarily. This creates a tension between equity and equality, as public health systems must decide whether to prioritize higher risk populations or distribute resources more evenly across all individuals. In addition, from the perspective of patients, deontology places strong emphasis on the duty to protect personal information, making the confidentiality of genetic data essential. Because BRCA results can reveal sensitive information not only about the individual but also about biological relatives, healthcare systems and testing companies carry a strict obligation to safeguard privacy and prevent misuse of data (“Genetic Information Privacy”). On a more individual level, this creates a moral tension between respecting patient confidentiality and the potential duty to inform at-risk family members (Hamilton et al). 

Additionally, screening programs must further protect populations who may face social, economic, or cultural vulnerability, in order to prevent exploitation, stigmatization, or unequal burdens of harm. While population genomic screening can promote disease prevention and early intervention, these public health goals must be balanced against individuals’ rights to decline testing and maintain control over personal medical decisions.

Those who lack advanced medical knowledge are more susceptible to coercion or uninformed decision-making and therefore can be considered more vulnerable than more informed patients. Organizations must remain accountable for the long-term social consequences of screening programs, including unintended harms such as stigma, discrimination, or misuse of genetic data. However, screening programs are not responsible for subsequent disease development, as these tests do not provide exact predictions of disease onset and participation is voluntary. Instead, they are responsible for spreading awareness and making sure that those who are eligible remain as informed as possible. 

Ethically responsible screening programs must also be culturally competent, meaning they account for religious beliefs, community values, and historical experiences that influence how different populations view genetic testing. Achieving this requires meaningful engagement with communities to understand the values and principles that shape their beliefs, rather than assumptions made by policymakers or scientists alone. Public health programs often collaborate with community leaders, patient advocacy groups, and cultural or religious organizations to understand concerns and build trust (Khoury and Dotson). However, no single individual can fully represent an entire population, so culturally competent programs must include diverse perspectives within a community and allow individuals to make informed decisions rather than imposing a uniform standard.

Ultimately, when employing a deontological framework, population genomic screening can be considered ethically justifiable under the adherence to specific duties. Governments have a duty to protect public health, and this includes a responsibility to prioritize populations at elevated risk for preventable disease. From the perspective of public health systems, directing screening efforts towards higher-risk groups reflects an equitable use of limited healthcare resources, not by treating all individuals identically, but by fulfilling the obligation to address need where it is greatest. However, this duty is not unlimited. A deontological approach also requires that individuals be treated as autonomous agents whose rights must be respected regardless of potential health benefits. Central among these rights is the protection of privacy. Genetic information is uniquely sensitive, as it reveals not only personal health risk, but also information about biological relatives, making the potential for misuse especially significant. As a result, any ethically acceptable screening must ensure strict safeguards regarding data collection, storage, and access, including clear limitations on third-party use by insurers, employers or other institutions (“Genetic Information Privacy”). With these ideas in mind, there is an inherent tension as the same programs designed to prevent disease and save lives also risk the exposure of individuals’ personal information. 

Overall, while deontology establishes the broader moral duties that must constrain screening programs, it does not determine whether such programs should be implemented overall. The duty of governments to promote public health encompasses the entire population of a country, making this statement reflect an equal rather than equitable perspective. The Ashkenazi Jewish community is much smaller in number and therefore the sole ethical decision cannot be based on deontology alone and must also consider the consequences of implementing or not implementing this form of testing.

Consequentialism:

Consequentialism is an ethical framework that judges the ethicality of an action based on its outcomes. From a consequentialist perspective, the ethical evaluation of BRCA genetic screening depends on its overall consequences, particularly whether it maximizes benefits and minimizes harm for individuals and society. These may contrast with one another as an individual benefit is not always necessarily equated to a societal benefit, considering the potential for different circumstances. From the patients’ perspective, BRCA testing offers significant advantages by identifying individuals at elevated risk for breast and ovarian cancer, allowing for earlier intervention. These preventive measures can substantially reduce cancer prevalence and mortality, improving quality of life and extending life expectancy. From the perspective of public health systems, screening within high-risk groups, such as Ashkenazi Jewish populations, can increase the efficiency of healthcare delivery and reduce long-term medical costs, further contributing to overall societal benefit (“Cost-Effectiveness, the QALY, and the evLY”).

However, consequentialism also requires careful consideration of potential harms associated with screening. Individuals undergoing BRCA testing may experience psychological distress, including anxiety, uncertainty, and internal conflict, particularly when navigating complex medical choices following a positive result. The implications of genetic information often extend beyond the individual, affecting family members and potentially creating tension around disclosure and shared risk (Hamilton et al). In addition, concerns surrounding data privacy, discrimination, and misuse of genetic information, especially in the context of direct-to-consumer testing, pose risks that may negatively impact overall well-being if not adequately addressed (“Genetic Information Privacy”). 

The ethical tension within consequentialism arises when the benefits of screening at the population level conflict with the burdens placed on singular individuals. Some argue that widespread genomic screening can be justified as a public health necessity, as early detection and prevention reduce disease prevalence and improve outcomes across entire populations. From this perspective, encouraging participation may be viewed as ethically supportable if it leads to greater overall good, even when individuals experience discomfort or social pressure. 

Referencing the history of sickle cell screening, this example illustrates how negative consequences can outweigh intended benefits when programs are poorly implemented. Mandatory testing, lack of informed consent, and racial discrimination resulted in stigma and mistrust, ultimately undermining both the integrity of policymaking and public health effectiveness (Markel). However, under the duties established in my deontological analysis, the benefits to the screening population have the potential to outweigh the burdens placed on patients. In doing so, we as a society can learn from poorly implemented screenings and work towards ensuring the protection of individuals as much as possible.

Consequently, consequentialism supports BRCA population genomic screening when its benefits, such as reduced cancer rates, improved quality of life, and lower mortality rates, clearly outweigh its risks (“Inherited Cancer Risk: BRCA Mutation”). From this perspective, the ethical justification of screening is grounded in its ability to produce the greatest overall health benefit for individuals and populations. However, these outcomes alone are not sufficient to deem a screening program ethically supportable, specifically for patients. Ethical implementation, therefore, requires upholding the constraints set by deontology in order to maximize positive outcomes. These duties function as the limits to which this form of screening can be implemented ethically or not. Thus, consequentialism argues that under these set conditions, population genomic screening for the BRCA mutation is ethically justifiable for both patients and public health systems given the potential life-saving medical information it can provide for a patient. In this way, the ethical acceptability of BRCA screening is not determined solely by scientific capability or medical outcomes, but by the conditions under which it is offered and experienced. 

Credit: Onit

Conclusion

The woman introduced at the beginning of this paper represents the real-world stakes of population genomic screening. What begins as a routine test quickly transforms into a series of deeply personal and complex decisions, revealing that genetic information is never purely medical. Instead, it carries lasting psychological, familial, and social consequences that extend far beyond the individual. This reality reveals the importance of evaluating BRCA mutation screening not only through its clinical effectiveness, but through the ethical conditions under which it is implemented. 

Through the application of deontological and consequentialist frameworks, it becomes clear that population genomic screening for BRCA mutations cannot be classified as simply ethical or unethical. Rather, its ethical justification depends on how it is designed, implemented, and experienced by both individual patients and public health systems. From a consequentialist perspective, screening offers substantial benefits, including earlier detection, reduced cancer mortality, and improved public health outcomes, particularly when targeted towards higher-risk groups such as Ashkenazi Jewish women. However, these benefits must be weighed against potential harms, including psychological distress, privacy risks, and social stigma, which may fall unevenly on individuals. At the same time, a deontological framework emphasizes that individuals must be treated as autonomous agents, requiring informed consent, transparent communication, and strict protection of personal genetic information regardless of broader outcomes. These duties are especially significant when considering differences in healthcare context, funding structures, and access, as these factors shape whether participation is truly voluntary and whether individuals are adequately supported throughout the screening process.  

Based on this analysis, population genomic screening for Ashkenazi Jewish women is ethically justified only under specific conditions for both patients and public health systems. For patients, participation must remain fully voluntary, supported by comprehensive, accessible genetic counseling before and after testing, ensuring informed and autonomous decision-making. For public health systems, screening must be equitably designed, with careful allocation of resources that balances prioritization of higher-risk populations with broader obligations to the general population. Across both perspectives, strong privacy protections must be enforced, particularly in the context of direct-to-consumer testing and data sharing, to prevent misuse or discrimination (“Genetic Information Privacy”). Finally, ethical implementation requires that screening programs be culturally sensitive and responsive to the communities they aim to serve. This includes meaningful engagement with community members and recognition of how historical experiences, religious values, and social dynamics influence trust in medical systems (Yi et al.). Ultimately, BRCA population genomic screening is ethically justified not by its medical benefits alone, but by the conditions under which it is implemented and its ability to balance public health outcomes with individual rights.

The failures of past screening efforts, particularly in the case of sickle cell anemia, demonstrate the consequences of neglecting these ethical responsibilities. Coercion, lack of informed consent, and racial bias not only caused harm to individuals, but also undermined trust in medical institutions, limiting the effectiveness of public health initiatives (Markel). These lessons highlight that scientific advancement alone is not sufficient; ethical implementation is essential to ensuring that the benefits of genomic screening come to fruition without reproducing harm. 

Lessons from population genomic screening more broadly can also inform the development of future large-scale genetic initiatives. These programs serve as models for both the promise and the risks of genomic medicine, demonstrating significant potential benefits to society when risks are thoughtfully considered and mitigated. As scientific capability advances, new technologies such as polygenic risk scores and AI-driven genomics expand both predictive power and ethical complexity. Polygenic risk scores estimate disease risk by analyzing multiple genetic variants across the genome, while AI-driven genomics uses machine learning to identify patterns in large genetic datasets and improve prediction accuracy. Although these tools may enhance early detection and prevention, they also raise concerns about overmedicalization, as individuals identified as “high risk” may face pressure to pursue intensive monitoring or preventive interventions despite uncertainty in predictions. This creates new ethical challenges surrounding how genetic risk is communicated, interpreted, and acted upon, requiring careful attention to accuracy, fairness, and potential psychological burdens (Fritzsche, Marie-Christine et al).

In conclusion, the ethical acceptability of BRCA screening lies not in the technology itself, but in the systems that deliver it. When designed with careful attention to autonomy, equity, cultural context, and evolving scientific capabilities, population genomic screening has the potential to significantly improve health outcomes while respecting individual rights. However, without these safeguards, even well-intentioned programs risk prioritizing public health goals at the expense of the individuals they are meant to serve. In navigating this balance, ethical decision-making in genomic medicine must pursue better outcomes without compromising the dignity and autonomy of individual patients.

Works Cited

“Ashkenazi Jewish Heritage and BRCA mutations.” Breast Cancer Surgery Melbourne, VIC, https://www.melbournebreastcancersurgery.com.au/ashkenazi-jewish-heritage-and-brca-mutations.html. Accessed 6 April 2026.

“BRCA/Genetics.” Sharsheret - The Jewish Breast Cancer and Ovarian Cancer Community Sharsheret, https://sharsheret.org. Accessed 12 April 2026.

Cline, Melissa, and Jill Holdren. “Genetic Testing: Not All Genetic Tests are Created Equal.” Facing Hereditary Cancer Empowered, 14 June 2022, https://www.facingourrisk.org/blog/not-all-genetic-tests-are-created-equal. Accessed 8 April 2026.

“Cost-Effectiveness, the QALY, and the evLY.” ICER, https://icer.org/our-approach/methods-process/cost-effectiveness-the-qaly-and-the-evlyg/. Accessed 12 April 2026.

“Data and Statistics on Sickle Cell Disease.” CDC, 15 May 2024, https://www.cdc.gov/sickle-cell/data/index.html. Accessed 13 April 2026.

Dar-Nimrod, Ilan, and Steven J Heine. “Genetic essentialism: on the deceptive determinism of DNA.” Psychological bulletin vol. 137,5 (2011): 800-18. doi:10.1037/a0021860

Dworkin, Gerald. “Paternalism (Stanford Encyclopedia of Philosophy).” Stanford Encyclopedia of Philosophy, 6 November 2002, https://plato.stanford.edu/entries/paternalism/#HardVsSoftPate. Accessed 13 April 2026.

Fritzsche, Marie-Christine et al. “Ethical layering in AI-driven polygenic risk scores-New complexities, new challenges.” Frontiers in genetics vol. 14 1098439. 26 Jan. 2023, doi:10.3389/fgene.2023.1098439

“Genetic Counseling.” Cleveland Clinic, 23 May 2022, https://my.clevelandclinic.org/health/articles/23086-genetic-counseling. Accessed 13 April 2026.

“Genetic Information Discrimination | U.S. Equal Employment Opportunity Commission.” EEOC, https://www.eeoc.gov/genetic-information-discrimination. Accessed 13 April 2026.

“Genetic Information Privacy.” Electronic Frontier Foundation, https://www.eff.org/issues/genetic-information-privacy. Accessed 13 April 2026.

“Genetic Testing FAQ.” Renown Health, https://www.renown.org/Health-Services/Genomic-Medicine-and-Genetics/genetic-testing-faq#aw8g3dxi0jd. Accessed 10 April 2026.

Hamilton, Jada G., et al. “Emotional Distress Following Genetic Testing for Hereditary Breast and Ovarian Cancer: A Meta-Analytic Review.” PubMed Central, 28 July 2009, https://pmc.ncbi.nlm.nih.gov/articles/PMC2807362/. Accessed 15 May 2026.

“The Human Genome Project.” Genome.gov, 19 March 2025, https://www.genome.gov/human-genome-project. Accessed 13 April 2026.

“Inherited Cancer Risk: BRCA Mutation.” Johns Hopkins Medicine, https://www.hopkinsmedicine.org/health/conditions-and-diseases/breast-cancer/inherited-cancer-risk-brca-mutation. Accessed 8 April 2026.

Khoury, Muin J., and David Dotson. “Population Genomic Screening is Here: We Need Evidence on Health Impact and Optimal Implementation | Blogs | CDC.” CDC Blogs, 21 June 2022, https://blogs.cdc.gov/genomics/2022/06/21/population-genomic-screening. Accessed 14 April 2026.

Lopatin, Asher. “Pikuach Nefesh: The Jewish Value of Saving a Life.” My Jewish Learning, https://www.myjewishlearning.com/article/pikuach-nefesh-the-overriding-jewish-value-of-human-life/. Accessed 16 May 2026.

Markel, Howard. “Promoting Safe and Effective Genetic Testing in the United States.” National Human Genome Research Institute, 01 April 2006, https://www.genome.gov/10002401/genetic-testing-reportappendix-6#:~:text=Several%20major%20criticisms%20of%20the,that%20time%20were%20urban%20dwellers. Accessed 13 April 2026.

Shuster, Evelyne. “Fifty Years Later: The Significance of the Nuremberg Code.” The New England Journal of Medicine, 1997, https://www.nejm.org/doi/full/10.1056/NEJM199711133372006#. Accessed 13 April 2026.

“Sickle cell anemia-Sickle cell anemia - Diagnosis & treatment.” Mayo Clinic, https://www.mayoclinic.org/diseases-conditions/sickle-cell-anemia/diagnosis-treatment/drc-20355882. Accessed 16 May 2026.

“Summary of the HIPAA Privacy Rule.” HHS.gov, 14 March 2025, https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/index.html. Accessed 13 April 2026.

Torr, Bethany et al. “The NHS England Jewish BRCA Testing Programme: overview after first year of implementation (2023-2024).” Journal of medical genetics vol. 62,2 69-73. 27 Jan. 2025, doi:10.1136/jmg-2024-110390

“Trust Center.” 23andMe Research Institute, https://www.23andmeresearchinstitute.org/trust-center. Accessed 13 April 2026.

Wen, Leana S. “Opinion | New research shows how to reduce breast cancer mammogram screenings.” The Washington Post, 10 February 2026, https://www.washingtonpost.com/

opinions/2026/02/10/breast-cancer-screening-mammograms/. Accessed 8 April 2026.

Yi, Haeseung, et al. “Understanding Social, Cultural, and Religious Factors Influencing Medical Decision-Making on BRCA1/2 Genetic Testing in the Orthodox Jewish Community.” Karger, 23 February 2024, https://karger.com/phg/article/27/1/57/

896943/Understanding-Social-Cultural-and-Religious. Accessed 8 April 2026.